TGFB2 and glioblastoma: GBM patients (N = 73) with high levels of TGFB2 methylation (TGFB2highMe) predicted a median OS time of 14 (95% CI: 12.4–23.1, death events = 50) months, which was similar to the median OS time of 14.4 (95% CI: 12.5–15.3, death events = 157) months for 219 patients with lower methylation levels (TGFB2lowMe).